Bavarian Nordic

Bavarian Nordic reports H1 2026 revenue of DKK 3,092m and an EBITDA margin of 35%, with Q2 at 45% and a gross margin of 61%. The company raised its full-year guidance to around DKK 5.7bn and its target EBITDA margin to about 30%; the stock jumped markedly in pre-market trading. Public Preparedness is now expected at DKK 2.5bn (DKK 2.3bn contractually secured), Travel Health remains robust, and the VIMKUNYA revenue forecast for 2026 was cut to DKK 200m due to delayed US uptake. Management also announced a share buyback program of DKK 750m and highlighted strong liquidity of DKK 2.3bn and headroom for M&A. » Más en de.investing.com

Bavarian Nordic has received a government contract worth more than DKK 700 million for the smallpox/mpox vaccine MVA‑BN, with deliveries starting in 2026 and the bulk of revenues expected in 2027. This brings contracts in the Public Preparedness segment for 2026 to around DKK 2,200 million. The company confirms its 2026 guidance and expects Public Preparedness revenues of DKK 2,300–2,500 million and group revenues of DKK 5,500–5,700 million with an EBITDA margin of around 28%. The buyer country's identity was not disclosed; the stock last traded near its 52‑week low. » Más en de.investing.com

Bavarian Nordic reported Q3 2025 revenue up 32% to DKK 4.8bn (Q3 revenue DKK 1.8bn) and a gross margin of 50%. The company confirmed the full-year revenue guidance of DKK 6bn and an expected EBITDA margin of 26–27%, after which the share fell about 7.2% to DKK 173.6. Positive highlights include the successful market launch of the chikungunya vaccine Vincunia in ten countries and a cash position of nearly DKK 3bn. » Más en de.investing.com